Relia Tech/Human Angiopoietin-1 / Ang-1/20 µg/300-048
市场价：
¥3400.00
美元价：
2040.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | 300-048 |
| Size | 20 µg |
| Price | 170 € |
| Source | HeLa cells |
| Label | His-Tag |
| Formulation | lyophilized |
| Purity Confirmation | > 97% by SDS-PAGE & HPLC analyses |
| Length [aa] | 485 |
| Molecular Weight | 60.0-70.0 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC). |
| Species Reactivity | Human |
| Synonyms | ANGPT1; AGP1; AGPT; ANG1 |
| Description | Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI (1). The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein. |
| Protein Sequence | MSNQRRSPENSGRRYNRIQHGQCAYTFILPEHDGNCRESTTDQYNTNALQRDAPHVEPDFSSQKLQHLEHMENYTQWLQKLENYIVENMKSEMAQIQQNAVQNHTATMLEIGTSLLSQTAEQTRKLTDVETQVLNQTSRLEIQLLENSLSTYKLEKQLLQQTNEILKIHEKNSLLEHKILEMEGKHKEELDTLKEEKENLQGLVTRQTYIIQELEKQLNRATTNNSVLQKQQLELMDTVHNLVNLCTKEGVLLKGGKREEEKPFRDCADVYQAGFNKSGIYTIYINNMPEPKKVFCNMDVNGGGWTVIQHREDGSLDFQRGWKEYKMGFGNPSGEYWLGNEFIFAITSQRQYMLRIELMDWEGNRAYSQYDRFHIGNEKQNYRLYLKGHTGTAGKQSSLILHGADFSTKDADNDNCMCKCALMLTGGWWFDACGPSNLNGMFYTAGQNHGKLNGIKWHYFKGPSYSLRSTTMMIRPLDFHHHHHH |
| Uniprot ID | Q15389 |
| Protein RefSeq | NP_001137.2 |
| mRNA RefSeq | NM_001146 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
